Pfizer Inc. (PFE)
After hours:
| Previous close | 53.99 |
| Open | 53.92 |
| Bid | 53.91 x 1800 |
| Ask | 53.92 x 4000 |
| Day's range | 53.51 - 54.40 |
| 52-week range | 38.48 - 61.71 |
| Volume | |
| Avg. volume | 27,492,225 |
| Market cap | 302.484B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 12.36 |
| EPS (TTM) | 4.36 |
| Earnings date | 26 July 2022 - 01 Aug 2022 |
| Forward dividend & yield | 1.60 (2.96%) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 59.15 |
- Zacks
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
- Business Wire
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex
